366 related articles for article (PubMed ID: 25967145)
1. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy.
Di Mitri D; Toso A; Alimonti A
Clin Cancer Res; 2015 Jul; 21(14):3108-12. PubMed ID: 25967145
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.
Hossain F; Al-Khami AA; Wyczechowska D; Hernandez C; Zheng L; Reiss K; Valle LD; Trillo-Tinoco J; Maj T; Zou W; Rodriguez PC; Ochoa AC
Cancer Immunol Res; 2015 Nov; 3(11):1236-47. PubMed ID: 26025381
[TBL] [Abstract][Full Text] [Related]
3. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
Bruno A; Mortara L; Baci D; Noonan DM; Albini A
Front Immunol; 2019; 10():771. PubMed ID: 31057536
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.
Yang Y; Li C; Liu T; Dai X; Bazhin AV
Front Immunol; 2020; 11():1371. PubMed ID: 32793192
[TBL] [Abstract][Full Text] [Related]
7. MDSCs in cancer: Conceiving new prognostic and therapeutic targets.
De Sanctis F; Solito S; Ugel S; Molon B; Bronte V; Marigo I
Biochim Biophys Acta; 2016 Jan; 1865(1):35-48. PubMed ID: 26255541
[TBL] [Abstract][Full Text] [Related]
8. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.
D'Amico L; Mahajan S; Capietto AH; Yang Z; Zamani A; Ricci B; Bumpass DB; Meyer M; Su X; Wang-Gillam A; Weilbaecher K; Stewart SA; DeNardo DG; Faccio R
J Exp Med; 2016 May; 213(5):827-40. PubMed ID: 27045006
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.
Zalfa C; Paust S
Front Immunol; 2021; 12():633205. PubMed ID: 34025641
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells in malignant melanoma.
Umansky V; Sevko A; Gebhardt C; Utikal J
J Dtsch Dermatol Ges; 2014 Nov; 12(11):1021-7. PubMed ID: 25263083
[TBL] [Abstract][Full Text] [Related]
12. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
13. Tolerance and immune suppression in the tumor microenvironment.
Ostrand-Rosenberg S
Cell Immunol; 2016 Jan; 299():23-9. PubMed ID: 26435343
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.
Park YJ; Song B; Kim YS; Kim EK; Lee JM; Lee GE; Kim JO; Kim YJ; Chang WS; Kang CY
Cancer Res; 2013 Sep; 73(18):5669-81. PubMed ID: 23867469
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
Marvel D; Gabrilovich DI
J Clin Invest; 2015 Sep; 125(9):3356-64. PubMed ID: 26168215
[TBL] [Abstract][Full Text] [Related]
16. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
17. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
Fujimura T; Mahnke K; Enk AH
J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
[TBL] [Abstract][Full Text] [Related]
18. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
Solito S; Bronte V; Mandruzzato S
J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
20. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
Lesokhin AM; Hohl TM; Kitano S; Cortez C; Hirschhorn-Cymerman D; Avogadri F; Rizzuto GA; Lazarus JJ; Pamer EG; Houghton AN; Merghoub T; Wolchok JD
Cancer Res; 2012 Feb; 72(4):876-86. PubMed ID: 22174368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
